Hairy cell leukemia variant and WHO classification correspondence Re: 5^th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

Michael Grever¹, Leslie Andritsos², Mirela Anghelina³, Evgeny Arons⁴, Versha Banerji⁵, Jacqueline Barrientos⁶, Seema A Bhat⁷, James Blachly⁷, Alessandro Broccoli⁸, Timothy Call⁹, Claire Dearden¹⁰, Sascha Dietrich¹¹, Monica Else¹², Narendranath Epperla⁷, Andrei Fagarasanu¹³, Brunangelo Falini¹⁴, Francesco Forconi¹⁵, Alessandro Gozzetti¹⁶, Paul Hampel⁹, David J Hermel¹⁷, Sunil Iyengar¹⁰, James B Johnston¹⁸, Gunnar Juliusson¹⁹, Robert J Kreitman⁴, Francesco Lauria²⁰, Gerard Lozanski²¹, Christopher C Oakes⁷, Sameer A Parikh⁹, Jae Park²², Graeme Quest²³, Kanti Rai²⁴, Farhad Ravandi²⁵, Tadeusz Robak²⁶, Kerry A Rogers⁷, Alan Saven¹⁷, John F Seymour²⁷, Tamar Tadmor²⁸, Martin S Tallman²⁹, Constantine S Tam³⁰, Enrico Tiacci¹⁴, Xavier Troussard³¹, Bernhard Wörmann³², Clive S Zent³³, Thorsten Zenz³⁴, Pier Luigi Zinzani⁸

Affiliations

¹ Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA. michael.grever@osumc.edu.
² Division of Hematology Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.
³ Center for Biostatistics, The Ohio State University, Columbus, OH, USA.
⁴ Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, MD, USA.
⁵ Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, and Paul Albrechtsen Research Institute CancerCare Manitoba, Winnipeg, MB, Canada.
⁶ Mount Sinai Medical Center Miami, Miami, FL, USA.
⁷ Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
⁸ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico "Sant'Orsola-Malpighi", and Department of Medical and Surgical Sciences - University of Bologna, Bologna, Italy.
⁹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
¹⁰ The Royal Marsden NHS Foundation Trust, London, UK.
¹¹ University Hospital of Düsseldorf, Düsseldorf, Germany.
¹² The Institute of Cancer Research, London, UK.
¹³ University of Alberta, Edmonton, AB, Canada.
¹⁴ Institute of Hematology and Center for Hemato-Oncological Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
¹⁵ Cancer Sciences and Haematology Department, University of Southampton and Cancer Care, Haematology Department, Southampton NHS University Hospital Trust, Southampton, UK.
¹⁶ Department of Medicine, Surgery and Neurosciences, University of Siena Policlinico S Maria alle Scotte, Siena, Italy.
¹⁷ Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA, USA.
¹⁸ Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.
¹⁹ Lund University/Dept of Hematology, Skåne University Hospital, Lund, Sweden.
²⁰ University of Siena, Siena, Italy.
²¹ Department of Pathology, The Ohio State University Medical Center, Columbus, OH, USA.
²² Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
²³ Pathology and Molecular Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.
²⁴ Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, USA.
²⁵ Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
²⁶ Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.
²⁷ Peter MacCallum Cancer Centre, Royal Melbourne Hospital & University of Melbourne, Melbourne, VIC, Australia.
²⁸ Hematology Unit, Bnai Zion Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
²⁹ Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
³⁰ Alfred Hospital and Monash University, Melbourne, VIC, Australia.
³¹ Department of Hematology, Centre Hospitalier Universitaire Cote de Nacre, Caen, France.
³² The Charité - Universitätsmedizin, Berlin, Germany.
³³ James P. Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
³⁴ Dept. of Medical Oncology & Haematology, Univerity Hospital and University of Zurich; The LOOP Zurich - Medical Research Center, Zurich, Switzerland.

PMID: 38851853
PMCID: PMC11216987
DOI: 10.1038/s41375-024-02280-0

Hairy cell leukemia variant and WHO classification correspondence Re: 5^th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

Michael Grever et al. Leukemia. 2024 Jul.

. 2024 Jul;38(7):1642-1644.

doi: 10.1038/s41375-024-02280-0. Epub 2024 Jun 8.

Authors

Affiliations

¹ Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA. michael.grever@osumc.edu.
² Division of Hematology Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.
³ Center for Biostatistics, The Ohio State University, Columbus, OH, USA.
⁴ Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, MD, USA.
⁵ Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, and Paul Albrechtsen Research Institute CancerCare Manitoba, Winnipeg, MB, Canada.
⁶ Mount Sinai Medical Center Miami, Miami, FL, USA.
⁷ Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.
⁸ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico "Sant'Orsola-Malpighi", and Department of Medical and Surgical Sciences - University of Bologna, Bologna, Italy.
⁹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
¹⁰ The Royal Marsden NHS Foundation Trust, London, UK.
¹¹ University Hospital of Düsseldorf, Düsseldorf, Germany.
¹² The Institute of Cancer Research, London, UK.
¹³ University of Alberta, Edmonton, AB, Canada.
¹⁴ Institute of Hematology and Center for Hemato-Oncological Research (CREO), University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
¹⁵ Cancer Sciences and Haematology Department, University of Southampton and Cancer Care, Haematology Department, Southampton NHS University Hospital Trust, Southampton, UK.
¹⁶ Department of Medicine, Surgery and Neurosciences, University of Siena Policlinico S Maria alle Scotte, Siena, Italy.
¹⁷ Division of Hematology and Oncology, Scripps Clinic, La Jolla, CA, USA.
¹⁸ Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.
¹⁹ Lund University/Dept of Hematology, Skåne University Hospital, Lund, Sweden.
²⁰ University of Siena, Siena, Italy.
²¹ Department of Pathology, The Ohio State University Medical Center, Columbus, OH, USA.
²² Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
²³ Pathology and Molecular Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.
²⁴ Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, USA.
²⁵ Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
²⁶ Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.
²⁷ Peter MacCallum Cancer Centre, Royal Melbourne Hospital & University of Melbourne, Melbourne, VIC, Australia.
²⁸ Hematology Unit, Bnai Zion Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
²⁹ Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
³⁰ Alfred Hospital and Monash University, Melbourne, VIC, Australia.
³¹ Department of Hematology, Centre Hospitalier Universitaire Cote de Nacre, Caen, France.
³² The Charité - Universitätsmedizin, Berlin, Germany.
³³ James P. Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
³⁴ Dept. of Medical Oncology & Haematology, Univerity Hospital and University of Zurich; The LOOP Zurich - Medical Research Center, Zurich, Switzerland.

PMID: 38851853
PMCID: PMC11216987
DOI: 10.1038/s41375-024-02280-0

No abstract available

PubMed Disclaimer

Conflict of interest statement

MA: received travel and accommodation expenses - Hairy Cell Leukemia Foundation; VB received consulting fees- Abbvie, AstraZeneca, BeiGene, Janssen, Merck, Lilly, honoraria- CTC Communications, Fusion MD, Oncology Education, funded grants or clinical trials- CIHR, LLSC, Lymphoma Canada, HCL Foundation, CLC.3, Lilly, AstraZeneca, Janssen, Abbvie, Gilead, patent on kinase inhibitors and methods of use ; JB: advisory board-Jannsen, Abbvie, Beigene, AstraZeneca, research support from Merck, Oncternal, Biomea; SAB: Advisory board- Pharmacyclics, AbbVie, Beigene and AstraZeneca, received research funding from AstraZeneca; FF: Honoraria- Abbvie, Janssen-cilag, Beigene, Astra-Zeneca, speakers bureau- Abbvie, Janssen-Cilag, Beigene, Astra-Zeneca, travel and accommodation- Abbvie, Janssen-Cilag, Beigene, consulting- BC platform, private clinical activity at Southampton General Hospital Solent Suite; MG: Consultant- Astra Zeneca, Pharmacyclics, Ascerta, Axio, Inc, research funding from Hairy Cell Leukemia Foundation for Patient Data Registry, travel expenses - Hairy Cell Leukemia Foundation, Scientific Board Chair - Hairy Cell Leukemia Foundation Scientific Board (no reimbursement), Deciphera Pharmaceuticals., Scientific Honorarium- University of Pittsburgh; SI: Advisory board, received speaker fees or conference support : AbbVie, Astra Zeneca, Beigene, BMS, Gilead, Janssen, Takeda; RK: Coinventor of the NIH patent for moxetumomab pasudotox, received research drug and/or research funding from AstraZeneca, Novartis, Pfizer, Genentech, and Teva; SAP: Research funding- provided to Mayo Clinic from Janssen, AstraZeneca, Merck, and Genentech, Honoraria - Pharmacyclics, Merck, AstraZeneca, Janssen, BeiGene, Genentech, MingSight Pharmaceuticals, Ascentage Pharma, Eli Lilly, Novalgen Limited, Kite Pharma, and AbbVie; JHP: received consulting fees from Affyimmune Therapeutics, Amgen, Autolus, Be Biopharma, Beigene, Bright Pharmaceutical Services, Inc., Caribou Biosciences, Curocell, Galapagos, In8Bio, Kite, Medpace, Minerva Biotechnologies, Pfizer, Servier, Sobi, and Takeda, received honoraria from OncLive, Physician Education Resource, and MJH Life Sciences, serves on scientific advisory board of Allogene Therapeutics, Artiva Biotherapeutics and Green Cross Biopharma, and received institutional research funding from Autolus, Genentech, Fate Therapeutics, InCyte, Servier, and Takeda; KR: Research funding (institution)-Genentech, AbbVie, and Novartis, consulting - Genentech, AbbVie, Pharmacyclics, AstraZeneca, Beigene, LOXO@Lilly, and Janssen; JFS: Advisory board, speakers’ bureau, research funding or expert testimony - AbbVie, Astra Zeneca, Beigene, BMS, Genor Bio, Gilead, Janssen, Roche. Consultant, expert testimony: TG Therapeutics; MST: Research funding-AbbVie, Orsenix, BioSight, Glycomiometics, Rafael Pharmaceuticals, Amgen, Advisory boards- AbbVie, Daiichi-Sankyo, Orsenix, KAHR Oncolyze, Jazz Parmaceuticals, BioSight, Innate Pharmaceuticals, Kura, Syros Pharmaceuticals, Ipsen Biopharmaceuticals, Royalties- UpToDate, Committees-Foghorn Therapeutics (Adjudication Committee), HOVON HO156 (DSMB), American Society of Hematology Executive Committee (2018-2021); CST: Honorarium from Janssen, AbbVie, Lilly, Beigene and Merck, research funding from Janssen, AbbVie and Beigene; ET: Advisory board for Innate Pharma, Kite/Gilead and Deciphera Pharmaceuticals, research funding from Roche, holder of a patent on the use of mutant BRAF as HCL biomarker; XT: Consultant for Abbvie, Lipomed, Beigene, fees from Deciphera; TZ: Advisory role- Roche, Gilead, Beigene, Lilly, Janssen, AstraZeneca, Abbvie, Incyte, Novartis; PLZ: Advisory board or Spekers bureau- Secur Bio, Celltrio, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, Astra Zeneca, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, ADC Therap., Incyte, Beigene. The other authors declare no competing interests.

References

1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48. doi: 10.1038/s41375-022-01620-2. - DOI - PMC - PubMed
1. Coupland SE, Du MQ, Ferry JA, deJong D, Khoury JD, Leoncini L, et al. The fifth edition WHO classification of mature B-Cell neoplasms: open questions for research. J Pathol. 2024;262:255–70. doi: 10.1002/path.6246. - DOI - PubMed
1. Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129:553–60. doi: 10.1182/blood-2016-01-689422. - DOI - PMC - PubMed
1. Matutes E. Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021? Expert Rev Hematol. 2021;14:355–63. doi: 10.1080/17474086.2021.1908121. - DOI - PubMed
1. Chihara D, Arons E, Stetler-Stevenson M, Yuan C, Wang HW, Zhou H, et al. Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Adv. 2021;5:4807–16. doi: 10.1182/bloodadvances.2021005039. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

P30 CA016058/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Hairy cell leukemia variant and WHO classification correspondence Re: 5^th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

Affiliations

Hairy cell leukemia variant and WHO classification correspondence Re: 5^th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

Authors

Affiliations

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources